Familial neuroendocrine tumor syndromes: from genetics to clinical practice.
Thanks to recent developments in molecular biology and cancer genetics, genetic testing has become widely available and useful in several kinds of familial tumor syndrome. However, the impact of genetic testing on medical management is not always straightforward. Clinicians have to consider the psychological impact and ethical complexities of communicating hereditary cancer risk information to families. This review notes some points on genetic counseling before and after genetic testing for familial neuroendocrine tumor syndromes.
Sakurai
Akihiro
A
Department of Preventive Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan. sakurai@sch.md.shinshu-u.ac.jp
Katai
Miyuki
M
Hashizume
Kiyoshi
K
Fukushima
Yoshimitsu
Y
D000328:Adult; D017281:Cost of Illness; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005817:Genetic Counseling / Q000941:ethics / Q000523:psychology; D020022:Genetic Predisposition to Disease; D030661:Genetic Privacy / Q000941:ethics; D005820:Genetic Testing / Q000941:ethics / Q000523:psychology; D006167:Guilt; D006801:Humans; D008297:Male; D009377:Multiple Endocrine Neoplasia / Q000175:diagnosis / Q000235:genetics* / Q000523:psychology / Q000628:therapy; D018358:Neuroendocrine Tumors / Q000175:diagnosis / Q000235:genetics* / Q000523:psychology / Q000628:therapy; D010375:Pedigree; D011379:Prognosis; D055815:Young Adult